New perspectives on neurochemical effects of amantadine in the brain of Parkinsonian patients: A PET - [ 11C]raclopride study

Journal of Neural Transmission

Volumn 109, Issue 10, 2002, Pages 1265-1274

  Moresco, R M ^a   Volonte, M A ^b   Messa, C ^a   Gobbo, C ^a   Galli, L ^a   Carpinelli, A ^a   Rizzo, G ^a   Panzacchi, A ^a   Franceschi, M ^c   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Santa Maria Hospital   (Italy)

Author keywords

D 2 dopamine receptor; Emission tomography; NMDA antagonist

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RACLOPRIDE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CAUDATE NUCLEUS; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROCHEMISTRY; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REDUCTION; STRIATE CORTEX;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; BRAIN CHEMISTRY; CAUDATE NUCLEUS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOSTRIATUM; PARKINSON DISEASE; PUTAMEN; RACLOPRIDE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036390350     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-002-0694-7     Document Type: Article

References (52)

1. Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591-592
2. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29: 142-147
3. Brown F, Redfern PH (1976) Studies on the mechanism of action of amantadine. Br J Pharmacol 58: 561-567
4. Castro SL, Zigmond MJ (2001) Stress-induced increase in extracellular dopamine in striatum: role of glutamatergic action via N-methyl-D-aspartate receptors in substan-tia nigra. Brain Res 901: 47-54
5. Cheramy A, Romo R, Godeheu G, Baruch P, Glowinski J (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus. II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 19: 1081-1090
6. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P (1999) Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34: 313-318
7. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16: 515-520
8. Farde L, Eriksson L, Blomqvist G, Halldin C (1989) Kinetic analysis of central [11C]raclopride binding to D2 dopamine receptors studied by PET. A comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9(5): 696-708
9. Fahn S, Elton RL, Committee MoU (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein R (eds) Recent development in Parkinson's disease II. Mac Millan, New York, pp 153-163
10. Fleming DM (2001) Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract 55: 189-195
11. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298: 27-30
12. Greenamyre JT, O'Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48: 977-981
13. Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12: 258-270
14. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411: 86-89
15. Hesselink MB, De Boer AG, Breimer DD, Danysz W (1999) Adaptation of NMDA and dopamine D2 but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm 106: 409-421
16. Keefe KA, Zigmond MJ, Abercrombie ED (1992) Extracellular dopamine in striatum: influence of nerve impulse activity in medial forebrain bundle and local glutamatergic input. Neuroscience 47: 325-332
17. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48: 627-640
18. Kemp BA, Gora ML (1993) Amantadine and fatigue of multiple sclerosis. Ann Pharmacother 27: 893-895
19. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM (1998) Evidence for striatal dopamine release during a video game. Nature 393: 266-268
20. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91-104
21. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995) Therapeutic brain concentration of the NMDA receptor antagonist amanta-dine. Neuropharmacology 34: 713-721
22. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn R, Brooks DJ, Frackowiak RS (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16: 42-52
23. Lannes B, Micheletti G (1997) Sensitization of the striatal dopaminergic system induced by chronic administration of a glutamate antagonist in the rat. Neurosci Biobehav Rev 21: 417-424
24. Lannes B, Bernard V, Bloch B, Micheletti G (1995) Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the D2 receptor gene. Neuroscience 65: 431-438
25. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-451
26. Micheletti G, Lannes B, Haby C, Borrelli E, Kempf E, Warter JM, Zwiller J (1992) Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Brain Res Mol Brain Res 14: 363-368
27. Micheletti G, Lannes B, Warter JM, Zwiller J (1993) Evidence for NMDA/D2 receptor-receptor interactions in the rat striatum. Adv Neurol 60: 128-132
28. Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M (1994) Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res 31: 255-258
29. Moghaddam B, Bolinao ML (1994) Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse 18: 337-342
30. Moresco RM, Loc'h C, Ottaviani M, Guibert B, Leviel V, Maziere M, Fazio F, Maziere B (1999) Effects of dopamine on the in vivo binding of dopamine D2 receptor radioligands in rat striatum. Nucl Med Biol 26: 91-98
31. Olanow CW, Koller WC (1998) An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 50: S1-S57
32. Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 22: 75-76
33. Page G, Peeters M, Maloteaux JM, Hermans E (2000) Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine. Eur J Pharmacol 403: 75-80
34. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2: 1137-1140
35. Porter RH, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614-623
36. Reichmann H, Sommer U, Fuchs G, Hefter H, Mark G, Muller T, Thumler R, Ulm G, Vieregge P (2000) Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease. J Neurol 247 [Suppl 4]: IV/40-41
37. Seeman P, Guan HC, Niznik HB (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96-97
38. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan L, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18: 18-25
39. Snow BJ, Mac Donald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-indiced dyskinesias in Parkinson's disease: a double blind, placebo-controlled study. Clin Neuropharmacol 23: 82-85
40. Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439-443
41. Takahashi T, Yamashita H, Zhang YX, Nakamura S (1996) Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41: 363-367
42. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B (1996) Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 46: 1430-1436
43. Toide K (1990) Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. Pharm Res 7: 670-672
44. Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, Kakiuchi T (2000) Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 37: 95-103
45. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46: 1551-1556
46. Verhagen Metman L, Del Dotto P, van deen Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatments for diskinesias and motor fluctiations in Parkinson's disease. Neurology 50: 1323-1326
47. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, et al. (1993) Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34: 609-613
48. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34: 35-43
49. Von Voigtlander PF, Moore KE (1971) Dopamine: release from the brain in vivo by amantadine. Science 174: 408-410
50. Von Voigtlander PF, Moore KE (1973) Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine. J Pharmacol Exp Ther 184: 542-552
51. Whitton PS, Maione S, Biggs CS, Fowler LJ (1994) N-methyl-d-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum in vivo. Brain Res 635: 312-316
52. Wu Y, Pearl SM, Zigmond MJ, Michael AC (2000) Inhibitory glutamatergic regulation of evoked dopamine release in striatum. Neuroscience 96: 65-72